Abstract: The present invention is directed to novel multicyclic molecules that mediate enzymatic activity. In particular, the compounds may be effective in the treatment of diseases or disease states related to the activity of PARP, VEGFR2, and MLK3 enzymes, including, for example, neurodegenerative diseases, inflammation, ischemia, and cancer.
Type:
Grant
Filed:
November 18, 2010
Date of Patent:
May 6, 2014
Assignee:
Cephalon, Inc.
Inventors:
Sankar Chatterjee, Reddeppa reddy Dandu, James L. Diebold, Derek D. Dunn, Robert L. Hudkins, Gregory J. Wells, Allison L. Zulli
Abstract: The present application provides a compound of formula (I) or a salt thereof, wherein R7, R8, R9, G, and X are as defined herein. This application further describes compositions comprising the same. Compounds of formula (I) and their salts have aPKC inhibitory activity, and may be used to treat proliferative disorders.
Type:
Application
Filed:
September 27, 2013
Publication date:
April 24, 2014
Applicants:
Cancer Research Technology Limited, Cephalon, Inc.
Inventors:
Henry J. Breslin, Bruce D. Dorsey, Benjamin J. Dugan, Katherine M. Fowler, Robert L. Hudkins, Eugen F. Mesaros, Nathaniel J.T. Monck, Emma L. Morris, Ikeoluwa Olowoye, Gregory R. Ott, Gregoire A. Pave, Jonathan R. Roffey, Christelle N. Soudy, Ming Tao, Craig A. Zificsak, Allison L. Zulli
Abstract: Compositions of modafinil and methods of treating neurologically related conditions with the administration of modafinil. Also compositions that include modafinil and one or more excipients such as diluents, disintegrants, binders and lubricants.
Type:
Grant
Filed:
August 21, 2012
Date of Patent:
April 1, 2014
Assignee:
Cephalon, Inc.
Inventors:
Craig S. Heacock, Alpa B. Parikh, Piyush R. Patel
Abstract: The present invention provides boronic acid compounds, boronic esters, and compositions thereof that can modulate apoptosis such as by inhibition of proteasome activity. The compounds and compositions can be used in methods of inducing apoptosis and treating diseases such as cancer and other disorders associated directly of indirectly with proteasome activity.
Type:
Application
Filed:
July 24, 2013
Publication date:
March 27, 2014
Applicant:
Cephalon, Inc.
Inventors:
Raffaella Bernardini, Alberto Bernareggi, Paolo G. Cassara, Sankar Chatterjee, Germano D'Arasmo, Sergio De Munari, Edmondo Ferretti, Mohamed Iqbal, Ernesto Menta, Patricia A. Messina McLaughlin, Ambrogio Oliva
Abstract: The present invention is directed to methods of treating disorders mediated by Histamine H3 receptors by administering novel pyridazinone derivatives. In particular, the pyridazinone compounds may be effective in the treatment of diseases or disease states related to the activity of the histamine H3 receptor, including, for example, neurodegenerative disorders, sleep/wake disorders, attention deficit hyperactivity disorder and cognition/cognitive disorders.
Type:
Grant
Filed:
August 3, 2011
Date of Patent:
March 18, 2014
Assignee:
Cephalon, Inc.
Inventors:
Edward R. Bacon, Thomas R. Bailey, Nadine C. Becknell, Sankar Chatterjee, Derek D. Dunn, Greg A. Hostetler, Robert L. Hudkins, Kurt A. Josef, Lars J. S. Knutsen, Ming Tao, Allison L. Zulli
Abstract: The present invention provides compounds of formula I: their use as H3 antagonists/inverse agonists, processes for their preparation, and pharmaceutical compositions thereof.
Type:
Grant
Filed:
December 22, 2011
Date of Patent:
February 11, 2014
Assignees:
Cephalon, Inc., Teva Sante
Inventors:
Edward R. Bacon, Thomas R. Bailey, Sankar Chatterjee, Derek D. Dunn, Greg A. Hostetler, Robert L. Hudkins, Brigitte Lesur, Babu G. Sundar, Allison L. Zulli, Christophe Yue
Abstract: The present invention provides compounds of Formula I or a pharmaceutically acceptable salt forms thereof, wherein R1, R2, R3, R4, R5, A and X are as defined herein, methods of treatment and uses thereof.
Type:
Application
Filed:
September 13, 2013
Publication date:
January 30, 2014
Applicant:
Cephalon, Inc.
Inventors:
Henry J. Breslin, Bruce D. Dorsey, Gregory R. Ott
Abstract: The present invention provides alternative forms of Compound I, processes to reproducibly make them and methods of treating patients using them.
Type:
Grant
Filed:
February 24, 2012
Date of Patent:
January 21, 2014
Assignee:
Cephalon, Inc.
Inventors:
Stephen Bierlmaier, Michael Christie, R. Scott Field, R. Curtis Haltiwanger, Linli He, Martin J. Jacobs, Michael Kress, Robert E. McKean, Dale R. Mowrey, Joseph Petraitis, Mehran Yazdanian, Veronique Courvoisier
Abstract: This application relates, in part, to compounds of the general Formula I and/or salts thereof, wherein X, R1A, R1B, R2, R3, R4, and R5 are as defined herein. The application also relates to compositions and methods of inhibiting at least JAK2 in subjects in recognized need thereof for the treatment of diseases or disorders for which inhibition of at least JAK2 is indicated.
Type:
Grant
Filed:
June 18, 2013
Date of Patent:
January 21, 2014
Assignee:
Cephalon, Inc
Inventors:
Matthew A. Curry, Bruce D. Dorsey, Benjamin J. Dugan, Diane E. Gingrich, Eugen F. Mesaros, Karen L. Milkiewicz
Abstract: Compounds of formula II are described: wherein D, n, Ra, Rb, and Rc are as herein defined, along with pharmaceutical compositions and methods of using compounds of formula II for treating or reducing the risk of peritoneal carcinomatosis in a patient.
Type:
Application
Filed:
August 26, 2013
Publication date:
January 2, 2014
Applicants:
Cephalon, Inc., University of Utah Research Foundation, University of Hawaii
Inventors:
Bruce D. Dorsey, Scott K. Kuwada, Jay P. Theroff, Craig A. Zificsak
Abstract: The present invention provides pharmaceutical formulations of lyophilized bendamustine suitable for pharmaceutical use. The present invention further provides methods of producing lyophilized bendamustine. The pharmaceutical formulations can be used for any disease that is sensitive to treatment with bendamustine, such as neoplastic diseases.
Type:
Application
Filed:
August 19, 2013
Publication date:
December 19, 2013
Applicant:
Cephalon, Inc.
Inventors:
Jason Edward Brittain, Joe Craig Franklin
Abstract: The present invention provides pharmaceutical formulations of lyophilized bendamustine suitable for pharmaceutical use. The present invention further provides methods of producing lyophilized bendamustine. The pharmaceutical formulations can be used for any disease that is sensitive to treatment with bendamustine, such as neoplastic diseases.
Type:
Grant
Filed:
December 19, 2012
Date of Patent:
December 17, 2013
Assignee:
Cephalon, Inc.
Inventors:
Jason Edward Brittain, Joe Craig Franklin
Abstract: Improved methods for the preparation and purification of bendamustine hydrochloride are described; such as method of preparing bendamustine hydrochloride comprising contacting a compound of formula HBI: with thionyl chloride
Abstract: The present invention is directed to methods of treating disorders mediated by Histamine H3 receptors by administering novel substituted spirocyclic piperidine derivatives according to Formula (I). In particular, the substituted spirocyclic piperidine derivatives may be effective in the treatment of diseases or disease states, including narcolepsy or sleep/wake disorders, feeding behavior disorders, eating disorders, obesity, cognition disorders, arousal disorders, memory disorders, mood disorders, mood attention alteration, attention deficit hyperactivity disorder (ADHD), Alzheimer's disease/dementia, schizophrenia, pain, stress, migraine, motion sickness, depression, psychiatric disorders, epilepsy, gastrointestinal disorders, respiratory disorders, inflammation, and myocardial infarction.
Type:
Application
Filed:
July 24, 2013
Publication date:
November 21, 2013
Applicant:
Cephalon, Inc.
Inventors:
Reddeppa reddy Dandu, Robert L. Hudkins, Babu G. Sundar